Pancreatic Cancer Research

ResearcherSeoul National UniversityActive in the last 2 years

Yun‐Hee Kim

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7571-9958; OpenAlex author ID A5100756278. Sources: OpenAlex.

Their work

Papers
15 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
33
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: none · 2021: 1 paper · 2022: none · 2023: 2 papers · 2024: 2 papers · 2025: 4 papers

Papers 15

  1. ATR inhibition promotes synergistic antitumor effect in platinum-resistant pancreatic cancer. Last author DOI 10.1016/j.bbadis.2024.167625↗
  2. Optimal Value of Mutant KRAS Circulating Tumor DNA for Predicting Prognosis and Monitoring in Patients with Pancreatic Adenocarcinoma: A Prospective Multicente… Co-author DOI 10.1093/clinchem/hvaf066↗
  3. Mutant KRAS and GATA6 Stratify Survival in Patients Treated with Chemotherapy for Pancreatic Adenocarcinoma: A Prospective Cohort Study. Co-author DOI 10.3390/cancers17050896↗
  4. Advanced Detection of Pancreatic Cancer Circulating Tumor Cells Using Biomarkers and Magnetic Particle Spectroscopy. Co-author DOI 10.7150/ntno.110074↗
  5. New Function Annotation of PROSER2 in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1021/acs.jproteome.3c00632↗
  6. Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer. Co-author DOI 10.1111/cas.16104↗
  7. Complexation of drug and hapten-conjugated aptamer with universal hapten antibody for pancreatic cancer treatment. Co-author DOI 10.1016/j.jconrel.2023.03.048↗
  8. Prevalence and Risk Factors of Germline Pathogenic Variants in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.4143/crt.2023.291↗
  9. Genomic Instability of Circulating Tumor DNA as a Prognostic Marker for Pancreatic Cancer Survival: A Prospective Cohort Study. Co-author DOI 10.3390/cancers13215466↗
  10. Development of Patient-Derived Preclinical Platform for Metastatic Pancreatic Cancer: PDOX and a Subsequent Organoid Model System Using Percutaneous Biopsy Sam… Last author DOI 10.3389/fonc.2019.00875↗
  11. Comprehensive Cancer Panel Sequencing Defines Genetic Diversity and Changes in the Mutational Characteristics of Pancreatic Cancer Patients Receiving Neoadjuva… Co-author DOI 10.5009/gnl18355↗
  12. Prognostic Implications of Multiplex Detection of KRAS Mutations in Cell-Free DNA from Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1373/clinchem.2017.283721↗
  13. Induction Chemotherapy with Gemcitabine and Cisplatin Followed by Simultaneous Integrated Boost-Intensity Modulated Radiotherapy with Concurrent Gemcitabine fo… Co-author DOI 10.4143/crt.2016.495↗
  14. Efficacy of pancreatic exocrine replacement therapy for patients with unresectable pancreatic cancer in a randomized trial. Co-author DOI 10.1016/j.pan.2016.09.001↗
  15. An RNA aptamer that specifically binds pancreatic adenocarcinoma up-regulated factor inhibits migration and growth of pancreatic cancer cells. Co-author DOI 10.1016/j.canlet.2011.08.027↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sang Myung Woo · 13 shared papers, 2016–2025 · strength 1.82
  2. Sun‐Young Kong · 11 shared papers, 2017–2025 · strength 1.61
  3. Woo Jin Lee · 10 shared papers, 2016–2025 · strength 1.30
  4. Sang‐Jae Park · 10 shared papers, 2016–2025 · strength 1.25
  5. Sung‐Sik Han · 9 shared papers, 2016–2025 · strength 1.05
  6. Jung Won Chun · 5 shared papers, 2023–2025 · strength 0.99
  7. Min Kyeong Kim · 6 shared papers, 2017–2025 · strength 0.73
  8. Yu‐Sun Lee · 4 shared papers, 2019–2025 · strength 0.63
  9. Kyong‐Ah Yoon · 6 shared papers, 2017–2024 · strength 0.61
  10. Mi Rim Lee · 3 shared papers, 2023–2025 · strength 0.56
  11. Tae Hyun Kim · 4 shared papers, 2016–2025 · strength 0.43
  12. Sang Hyub Lee · 2 shared papers, 2025 · strength 0.42
  13. Ali Dinari · 1 shared paper, 2025 · strength 0.33
  14. Jungwon Yoon · 1 shared paper, 2025 · strength 0.33
  15. Jin‐Hyeok Hwang · 2 shared papers, 2021–2025 · strength 0.33
  16. Sung Yong Choi · 2 shared papers, 2019–2024 · strength 0.27
  17. Eui Joo Kim · 1 shared paper, 2025 · strength 0.22
  18. Min Kyu Jung · 1 shared paper, 2025 · strength 0.22
  19. Dong‐Won Ahn · 1 shared paper, 2025 · strength 0.22
  20. Hyeong Min Park · 1 shared paper, 2025 · strength 0.22
  21. Hye Won Shon · 1 shared paper, 2025 · strength 0.20
  22. Woo Hyun Paik · 1 shared paper, 2025 · strength 0.20
  23. In Rae Cho · 1 shared paper, 2025 · strength 0.20
  24. Sung Jun Kim · 1 shared paper, 2025 · strength 0.20
  25. Ji Kon Ryu · 1 shared paper, 2025 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.